for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jazz Pharmaceuticals PLC

JAZZ.O

Latest Trade

116.64USD

Change

3.26(+2.88%)

Volume

155,814

Today's Range

116.51

 - 

119.47

52 Week Range

86.88

 - 

154.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
113.38
Open
118.49
Volume
155,814
3M AVG Volume
14.21
Today's High
119.47
Today's Low
116.51
52 Week High
154.24
52 Week Low
86.88
Shares Out (MIL)
55.33
Market Cap (MIL)
6,273.36
Forward P/E
9.56
Dividend (Yield %)
--

Next Event

Jazz Pharmaceuticals PLC at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Jazz Pharma Reports Q1 Diluted EPS Loss 2.82 USD Vs 1.47 USD Profit Year Ago

Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

Jazz Pharma Says Porton Biopharma Entered Into New Agreement With New Partner To Commercialize & Distribute Erwinaze

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Industry

Biotechnology & Drugs

Contact Info

Fifth Fl

Waterloo Exchange, Waterloo Road

4

Ireland

+353.1.6347800

https://www.jazzpharma.com/

Executive Leadership

Bruce C. Cozadd

Chairman of the Board, Chief Executive Officer

Daniel N. Swisher

President, Chief Operating Officer

Renee D. Gala

Chief Financial Officer, Executive Vice President

Robert Iannone

Executive Vice President, Research and Development

Michael P. Miller

Executive Vice President - U.S. Commercial

Key Stats

1.95 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.6K

2018

1.9K

2019

2.2K

2020(E)

2.2K
EPS (USD)

2017

11.040

2018

13.700

2019

16.230

2020(E)

11.860
Price To Earnings (TTM)
23.56
Price To Sales (TTM)
2.87
Price To Book (MRQ)
2.24
Price To Cash Flow (TTM)
9.54
Total Debt To Equity (MRQ)
57.34
LT Debt To Equity (MRQ)
56.15
Return on Investment (TTM)
5.79
Return on Equity (TTM)
5.34

Latest News

Latest News

BRIEF-Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Jazz Pharma Reports Q1 Diluted EPS Loss 2.82 USD Vs 1.47 USD Profit Year Ago

* Q1 DILUTED EPS LOSS 2.82 USD VERSUS 1.47 USD PROFIT YEAR AGO

BRIEF-Jazz Pharma Stops Enrollment In Phase 3 Study Evaluating Defibrotide For Prevention Of Veno-Occlusive Disease

* JAZZ PHARMACEUTICALS STOPS ENROLLMENT IN PHASE 3 STUDY EVALUATING DEFIBROTIDE FOR PREVENTION OF VENO-OCCLUSIVE DISEASE

BRIEF-Jazz Pharma Says Porton Biopharma Entered Into New Agreement With New Partner To Commercialize & Distribute Erwinaze

* JAZZ PHARMACEUTICALS - PORTON BIOPHARMA LIMITED ENTERED INTO NEW AGREEMENT WITH NEW PARTNER TO COMMERCIALIZE & DISTRIBUTE ERWINAZE

BRIEF-Jazz Pharmaceuticals Sees A Limited Financial Impact From COVID-19

* JAZZ PHARMACEUTICALS PLC - SEES A LIMITED FINANCIAL IMPACT FROM COVID-19

BRIEF-Jazz Pharmaceuticals - PDUFA Goal Date For An FDA Decision For Jzp-258 Is July 21, 2020

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR JZP-258 FOR CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

Jazz Pharma's sleep disorder drug gets European panel backing

Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday.

BRIEF-Jazz Pharma's sleep disorder drug gets European panel backing

* EMA - CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR ISTURISA (OSILODROSTAT) FOR THE TREATMENT OF CUSHING’S SYNDROME

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

Jazz Pharmaceuticals to settle U.S. probe for $57 million

Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Jazz Pharmaceuticals to settle U.S. probe for $57 million

Jazz Pharmaceuticals plc on Tuesday said that it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

* JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA

BRIEF-Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79

* JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL EVALUATING DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)

* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA

Pennsylvania man admits to trading on tips about drug company

A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc <JAZZ.O> was planning to be acquired.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up